CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 61 enrolled
Drug / intervention
Doxazosin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02989493
NCT02989493Phase 2Completed
CompareCT.gov

Randomized Controlled Trial Targeting Noradrenergic Stress Mechanisms in Alcoholism With Doxazosin

University of Wisconsin, Madison·interventional·Posted Dec 12, 2016·Updated Mar 18, 2021

In Brief

A Phase 2 clinical trial evaluating Doxazosin and Placebo for Alcoholism. Completed, enrolled 61 participants across 1 site.

Detailed Summary

Double-blind, placebo controlled, randomized controlled trial (RCT) for Alcohol Use Disorder examining the effects of doxazosin, a norepinephrine alpha1 receptor antagonist, on stress reactivity and clinical outcomes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
CollaboratorsNational Institute on Alcohol Abuse and Alcoholism (NIAAA)

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 12, 2016
Enrollment StartApr 12, 2017
Primary CompletionMar 13, 2020
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 9.6 years ago

Interventions

Doxazosindrug

Doxazosin

Placeboother

Placebo